Saturday 17 October 2026 Export TNDM’s income statement to Excel — free account

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024. In the quarter to June 2026, revenue grew 5.77%, EPS grew 60.3%, free cash flow fell 146.3% and total debt rose 94.9%, each against the same quarter a year earlier.

16.17 0.35 −2.12%

Follow TNDM

Alert me

Market cap: $1.2B
P/E: 0.0×
Fwd P/E: −28.1×
Dividend yield: —
F-score: 3/9
Altman Z: 0.19
Beneish M: −3.10
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	2	—	—	—	—	—	—	—

Insider Ownership 0.42%

Capital & Financial Ratios $m

Market Cap 1,150.00

Revenue 1,041.42

Net Income (63.31)

Free Cash Flow (26.62)

Net Debt 146.58

Current Ratio 3.18

Debt/Equity 4.62

P/E ratio 0.00

Fwd P/E (28.10)

P/S ratio 1.07

P/B ratio 8.56

Past 5Y EPS Growth —

This Y EPS Growth 53.99%

Next Y EPS Growth 119.06%

Next Y revenue growth 5.64%

Next 5Y EPS Growth 44.82%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 17.66%

10-year low 10-year high

P/B against its own 10 years 35.19%

10-year low 10-year high

EV/Sales against its own 10 years 20.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	468	438	293	456
Receivables	106	115	165	162
Inventory	158	150	129	135
Other	—	—	—	—
	748	724	618	805

	2023	2024	2025	Q'26
Payables	50	45	47	64
ST’ Debt	—	—	—	—
Other	28	49	75	81
	195	247	243	253

Compound Annual Growth %

	10y	5y	3y
Sales	30.13%	15.26%	8.19%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	9.35%	(15.78%)	(29.35%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	247	255	—	—	—
’25	234	241	249	290	1,015
’24	192	222	244	283	940
’23	169	196	186	197	748
’22	176	200	205	221	801
’21	141	172	180	210	703
’20	98	109	124	168	499

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	11	(35)	—	—	—
’25	(18)	(9)	8	10	(10)
’24	(8)	(5)	27	11	24
’23	(18)	(6)	0	(7)	(32)
’22	14	7	24	6	50
’21	29	29	34	20	111
’20	(21)	15	15	15	25

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	5	(39)	—	—	—
’25	(21)	(16)	4	3	(30)
’24	(12)	(12)	22	(39)	(41)
’23	(29)	(14)	(5)	(35)	(83)
’22	11	(6)	2	0	8
’21	25	18	31	14	88
’20	(27)	1	8	11	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	(0.31)	—	—	—
’25	(1.97)	(0.78)	(0.31)	(0.01)	(3.04)
’24	(0.65)	(0.47)	(0.35)	0.01	(1.47)
’23	(1.92)	(0.55)	(0.51)	(0.46)	(3.43)
’22	(0.23)	(0.24)	(0.76)	(0.25)	(1.47)
’21	(0.08)	0.06	0.09	0.16	0.24
’20	(0.25)	(0.45)	(0.15)	0.22	(0.56)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	16.00	2.15	2.14	32.00	43.69	76.19	33.52	13.82	21.85	9.98	Analyst estimates 2026–2028 Powerpack
	High	118.00	30.00	52.55	74.81	123.74	155.86	150.64	47.18	53.69	38.28
People
People	Employees	591	574	653	1,043	1,500	2,000	2,600	2,400	2,650	2,500
	Revenue/emp, $m	0.14	0.19	0.28	0.35	0.33	0.35	0.31	0.31	0.35	0.41
Income, $m
Income, $m	Revenue	84	108	184	362	499	703	801	748	940	1,015
	Gross margin, %	28.00	40.98	48.85	53.60	52.23	53.53	51.54	49.17	52.07	53.81
	EBT	(83)	(73)	(123)	(25)	(36)	16	(93)	(220)	(92)	(200)
	EBT margin, %	(99.07)	(67.87)	(66.66)	(6.79)	(7.27)	2.26	(11.59)	(29.46)	(9.77)	(19.74)
	Net income	(83)	(73)	(123)	(25)	(34)	16	(95)	(223)	(96)	(205)
	Depreciation	5	7	8	6	19	16	20	22	16	16
Per share, $
Per share, $	Revenue	27.56	18.95	3.82	6.19	8.18	11.16	12.49	11.51	14.37	15.08
	Earnings	(27.30)	(12.87)	(2.55)	(0.42)	(0.56)	0.25	(1.47)	(3.43)	(1.47)	(3.04)
	Cash flow	(20.01)	(11.65)	(0.17)	0.72	0.40	1.77	0.79	(0.49)	0.37	(0.14)
	Capex	(2.92)	(1.01)	(0.06)	(0.33)	(0.53)	(0.37)	(0.67)	(0.79)	(1.00)	(0.30)
	Free cash flow	(22.93)	(12.66)	(0.23)	0.38	(0.12)	1.39	0.12	(1.28)	(0.63)	(0.44)
	Book value	(1.94)	(5.13)	2.73	3.33	6.01	6.87	6.86	4.83	4.02	2.31
	Shares, m	3	6	48	59	61	63	64	65	65	67
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	627.17	0.00	0.00	0.00	0.00
	P/S	0.76	0.13	9.94	9.63	11.70	13.49	3.57	2.46	2.51	1.46
	P/B	0.00	0.00	13.92	17.89	15.93	21.89	6.50	5.87	8.96	9.53
	EV/Sales	1.04	0.71	9.66	9.18	11.13	13.01	3.15	2.22	2.37	1.47
	EV/FCF	(1.25)	(1.07)	(156.04)	149.17	(728.34)	104.05	336.09	(19.87)	(34.69)	(15.13)
Cash, $m
Cash, $m	Operating cash flow	(61)	(66)	(8)	42	25	111	50	(32)	24	(10)
	Capex	(9)	(6)	(3)	(20)	(32)	(24)	(43)	(52)	(66)	(20)
	Free cash flow	(70)	(72)	(11)	22	(8)	88	8	(83)	(41)	(30)
Balance, $m
Balance, $m	Working capital	61	28	122	177	533	680	685	553	477	375
	Total debt	79	77	—	14	203	281	283	285	308	310
	Net debt	23	62	(129)	(162)	(282)	(342)	(334)	(183)	(130)	17
	Shareholders’ equity	(6)	(29)	131	195	366	433	440	314	263	155
Returns, %
Returns, %	ROA	(70.38)	(70.31)	(81.30)	(9.30)	(6.60)	1.92	(9.66)	(22.20)	(10.00)	(22.15)
	ROIC	(278.83)	(118.44)	(1,240.85)	(32.14)	(5.90)	15.60	(54.60)	(111.48)	(46.57)	(67.83)
	ROE	(290.04)	416.44	(240.11)	(15.17)	(12.25)	3.89	(21.67)	(59.08)	(33.30)	(97.88)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BVS Bioventus Inc.	$1.2B	16.4×	21.4×	+3.76% (above 0%: growing)	+345.45% (above 0%: growing)	−25.11% (below 0%: shrinking)	68.97%	12.48%	Compare
TNDM Tandem Diabetes Care, Inc.	$1.2B	— (loss-making)	— (loss-making)	+5.77% (above 0%: growing)	n/m	−146.34% (below 0%: shrinking)	56.87%	(5.42%)
IRMD iRadimed Corporation	$1.1B	48.5×	48.7×	+0.28% (above 0%: growing)	−8.89% (below 0%: shrinking)	+11.66% (above 0%: growing)	74.07%	31.23%	Compare
ENOV Enovis Corporation	$1.1B	— (loss-making)	195×	+3.23% (above 0%: growing)	n/m	+815.79% (above 0%: growing)	61.64%	2.99%	Compare
AORT Artivion, Inc.	$1.1B	— (loss-making)	142×	+11.32% (above 0%: growing)	n/m	−202.47% (below 0%: shrinking)	64.03%	(6.65%)	Compare
CBLL CeriBell, Inc.	$1.1B	— (loss-making)	— (loss-making)	+32.54% (above 0%: growing)	n/m	−68.63% (below 0%: shrinking)	92.32%	(71.11%)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
Median of peers	$1.1B	—	37.4×	+5.79%	—	−6.38%	65.02%	3.80%

All 149 Medical Devices stocks →

Tandem Diabetes Care, Inc. (TNDM) key facts

Concern: Tandem Diabetes Care, Inc. reported a net loss of $204.7 million, or a loss of $3.04 per share, for fiscal 2025.
Strength: Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024.
Tandem Diabetes Care, Inc. (TNDM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TNDM traded at $16.17, a market capitalization of $1.2 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.1× sales.
Return on equity was −97.9% and debt-to-equity 4.62.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.19 (distress zone) for fiscal 2025.